Arrowhead Pharmaceuticals, Inc. (ARWR)
USD 14.42
(2.71%)
USD 14.42
(2.71%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -175.67 Million USD | -5.41% |
| 2022 | -162.28 Million USD | -26.81% |
| 2021 | -132.58 Million USD | -61.4% |
| 2020 | -87.21 Million USD | -232.89% |
| 2019 | 65.62 Million USD | 227.02% |
| 2018 | -51.23 Million USD | -55.65% |
| 2017 | -29.68 Million USD | 55.19% |
| 2016 | -78.46 Million USD | 23.25% |
| 2015 | -89.6 Million USD | -132.63% |
| 2014 | -47.38 Million USD | -179.51% |
| 2013 | -20.1 Million USD | 19.86% |
| 2012 | -19.34 Million USD | -73.37% |
| 2011 | -8.51 Million USD | -8.66% |
| 2010 | -6.68 Million USD | 47.78% |
| 2009 | -18.16 Million USD | 44.4% |
| 2008 | -33.24 Million USD | 8.33% |
| 2007 | -35.68 Million USD | -87.82% |
| 2006 | -19.42 Million USD | -77.31% |
| 2005 | -8.94 Million USD | -313.63% |
| 2004 | -2.67 Million USD | -2742.71% |
| 2003 | -94.34 Thousand USD | 93.54% |
| 2002 | -1.4 Million USD | -795.53% |
| 2001 | -102.73 Thousand USD | 16.61% |
| 2000 | -101.61 Thousand USD | -223.35% |
| 1999 | -48.09 Thousand USD | 384.26% |
| 1998 | -15.11 Thousand USD | -108.7% |
| 1997 | -54.83 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -171.35 Million USD | -42.42% |
| 2024 Q1 | -129.05 Million USD | -29.23% |
| 2024 Q2 | -121.66 Million USD | 10.72% |
| 2023 Q1 | -42.13 Million USD | 49.74% |
| 2023 Q4 | -99.86 Million USD | -5.18% |
| 2023 Q2 | 55.4 Million USD | 231.49% |
| 2023 Q3 | -94.94 Million USD | -271.38% |
| 2023 FY | - USD | -5.41% |
| 2022 Q3 | -70.31 Million USD | -259.27% |
| 2022 Q4 | -83.83 Million USD | -19.22% |
| 2022 Q1 | -60.74 Million USD | 2.61% |
| 2022 Q2 | 44.14 Million USD | 172.67% |
| 2022 FY | - USD | -26.81% |
| 2021 Q4 | -62.37 Million USD | -108.83% |
| 2021 Q1 | -22.2 Million USD | 54.07% |
| 2021 FY | - USD | -61.4% |
| 2021 Q2 | -26.31 Million USD | -18.5% |
| 2021 Q3 | -29.87 Million USD | -13.52% |
| 2020 Q1 | -3.59 Million USD | -133.52% |
| 2020 Q3 | -14.4 Million USD | 30.95% |
| 2020 FY | - USD | -232.89% |
| 2020 Q4 | -48.34 Million USD | -235.51% |
| 2020 Q2 | -20.86 Million USD | -480.79% |
| 2019 Q1 | 12.12 Million USD | 221.96% |
| 2019 Q3 | 19.59 Million USD | -15.47% |
| 2019 FY | - USD | 227.02% |
| 2019 Q2 | 23.18 Million USD | 91.26% |
| 2019 Q4 | 10.72 Million USD | -45.3% |
| 2018 Q1 | -13.12 Million USD | -55.0% |
| 2018 FY | - USD | -55.65% |
| 2018 Q3 | -14.74 Million USD | -6.36% |
| 2018 Q4 | -9.94 Million USD | 32.58% |
| 2018 Q2 | -13.86 Million USD | -5.63% |
| 2017 Q3 | -4.61 Million USD | 6.11% |
| 2017 Q1 | -15.2 Million USD | 6.84% |
| 2017 FY | - USD | 55.19% |
| 2017 Q4 | -8.46 Million USD | -83.47% |
| 2017 Q2 | -4.91 Million USD | 67.67% |
| 2016 Q2 | -20.83 Million USD | -12.46% |
| 2016 Q4 | -16.31 Million USD | 11.37% |
| 2016 Q1 | -18.52 Million USD | 25.3% |
| 2016 FY | - USD | 23.25% |
| 2016 Q3 | -18.4 Million USD | 11.62% |
| 2015 Q2 | -29.39 Million USD | -8.16% |
| 2015 FY | - USD | -132.63% |
| 2015 Q1 | -27.18 Million USD | -56.05% |
| 2015 Q3 | -15.14 Million USD | 48.47% |
| 2015 Q4 | -24.79 Million USD | -63.7% |
| 2014 Q1 | -3.03 Million USD | -45.52% |
| 2014 Q3 | -13.18 Million USD | -67.71% |
| 2014 Q4 | -17.41 Million USD | -32.13% |
| 2014 FY | - USD | -179.51% |
| 2014 Q2 | -7.86 Million USD | -159.17% |
| 2013 Q1 | -4.42 Million USD | 6.59% |
| 2013 Q2 | -4.85 Million USD | -9.81% |
| 2013 Q3 | -3.48 Million USD | 28.34% |
| 2013 Q4 | -2.08 Million USD | 40.12% |
| 2013 FY | - USD | 19.86% |
| 2012 FY | - USD | -73.37% |
| 2012 Q3 | -4.96 Million USD | -30.97% |
| 2012 Q1 | -5.03 Million USD | -75.77% |
| 2012 Q2 | -3.78 Million USD | 24.75% |
| 2012 Q4 | -4.73 Million USD | 4.59% |
| 2011 FY | - USD | -8.66% |
| 2011 Q4 | -2.86 Million USD | -80.75% |
| 2011 Q3 | -1.58 Million USD | 26.08% |
| 2011 Q2 | -2.14 Million USD | -53.05% |
| 2011 Q1 | -1.4 Million USD | 38.27% |
| 2010 Q4 | -2.26 Million USD | 36.4% |
| 2010 FY | - USD | 47.78% |
| 2010 Q3 | -3.56 Million USD | -77.64% |
| 2010 Q2 | -2 Million USD | -1.14% |
| 2010 Q1 | -1.98 Million USD | 27.36% |
| 2009 Q4 | -2.73 Million USD | -38.09% |
| 2009 FY | - USD | 44.4% |
| 2009 Q1 | -9.01 Million USD | 20.02% |
| 2009 Q2 | -5.02 Million USD | 44.23% |
| 2009 Q3 | -1.98 Million USD | 60.63% |
| 2008 FY | - USD | 8.33% |
| 2008 Q4 | -11.27 Million USD | -17.09% |
| 2008 Q3 | -9.62 Million USD | -42.13% |
| 2008 Q1 | -6.59 Million USD | 41.88% |
| 2008 Q2 | -6.77 Million USD | -2.66% |
| 2007 FY | - USD | -87.82% |
| 2007 Q2 | -8.19 Million USD | -93.22% |
| 2007 Q1 | -4.24 Million USD | 43.9% |
| 2007 Q3 | -13.14 Million USD | -60.33% |
| 2007 Q4 | -11.35 Million USD | 13.61% |
| 2006 FY | - USD | -77.31% |
| 2006 Q1 | -3.82 Million USD | -108.72% |
| 2006 Q2 | -3.9 Million USD | -1.93% |
| 2006 Q3 | -4.37 Million USD | -12.22% |
| 2006 Q4 | -7.56 Million USD | -72.75% |
| 2005 Q3 | -3.16 Million USD | 24.45% |
| 2005 Q4 | -1.83 Million USD | 42.01% |
| 2005 Q1 | -1.94 Million USD | -58.96% |
| 2005 Q2 | -4.18 Million USD | -114.8% |
| 2005 FY | - USD | -313.63% |
| 2004 Q4 | -1.22 Million USD | -146.35% |
| 2004 Q3 | -497.56 Thousand USD | 37.73% |
| 2004 Q1 | -79.73 Thousand USD | -352.92% |
| 2004 Q2 | -799.08 Thousand USD | -902.22% |
| 2004 FY | - USD | -2742.71% |
| 2003 FY | - USD | 93.54% |
| 2003 Q4 | 71.72 Thousand USD | -30.57% |
| 2003 Q3 | -13.39 Thousand USD | 52.68% |
| 2003 Q2 | -27.76 Thousand USD | 6.77% |
| 2003 Q1 | -30.56 Thousand USD | 97.68% |
| 2002 Q4 | -1.31 Million USD | -2710.05% |
| 2002 FY | - USD | -795.53% |
| 2002 Q1 | -25.7 Thousand USD | 26.43% |
| 2002 Q2 | -22.36 Thousand USD | -173.08% |
| 2002 Q3 | -43.86 Thousand USD | 34.64% |
| 2001 Q3 | -33.8 Thousand USD | -4.86% |
| 2001 FY | - USD | 16.61% |
| 2001 Q2 | -23.75 Thousand USD | 46.91% |
| 2001 Q1 | -33.01 Thousand USD | 48.56% |
| 2001 Q4 | -29.86 Thousand USD | -5.43% |
| 2000 Q2 | -23.43 Thousand USD | 24.43% |
| 2000 Q1 | -30.85 Thousand USD | 60.19% |
| 2000 FY | - USD | -223.35% |
| 2000 Q3 | -21.1 Thousand USD | 10.62% |
| 2000 Q4 | -26.22 Thousand USD | -448.87% |
| 1999 FY | - USD | 384.26% |
| 1999 Q2 | -30 Thousand USD | 0.0% |
| 1999 Q4 | -80 Thousand USD | -112.9% |
| 1999 Q3 | 620 Thousand USD | 2166.67% |
| 1999 Q1 | -30 Thousand USD | 0.0% |
| 1998 Q4 | -30 Thousand USD | -200.0% |
| 1998 Q3 | -10 Thousand USD | 50.0% |
| 1998 FY | - USD | -108.7% |
| 1998 Q2 | -20 Thousand USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Absci Corporation | -95.45 Million USD | -84.033% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 7.186% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 31.974% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -1676.815% |
| Apollomics, Inc. | -171.74 Million USD | -2.285% |
| 180 Life Sciences Corp. | -22.13 Million USD | -693.674% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -460.286% |
| Bicycle Therapeutics plc | -183.4 Million USD | 4.214% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | -134.809% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | -6.197% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -715.6% |
| Chimerix, Inc. | -92.97 Million USD | -88.947% |
| CRISPR Therapeutics AG | -202.7 Million USD | 13.334% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 845.225% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -154.593% |
| Fortress Biotech, Inc. | -133.64 Million USD | -31.449% |
| Fortress Biotech, Inc. | -133.64 Million USD | -31.449% |
| Gritstone bio, Inc. | -126.86 Million USD | -38.474% |
| Allakos Inc. | -189.91 Million USD | 7.5% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -262.382% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -49.317% |
| Cytokinetics, Incorporated | -456.68 Million USD | 61.533% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | -85.363% |
| Innoviva, Inc. | 248.96 Million USD | 170.562% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -114606.593% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1389.294% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | -39.593% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -1363295.419% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | -71.779% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | -98.573% |
| ImmuCell Corporation | -2.5 Million USD | -6915.439% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | -34.696% |
| Incyte Corporation | 919.42 Million USD | 119.107% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | -34.727% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -2649.762% |
| Mustang Bio, Inc. | -48.06 Million USD | -265.504% |
| MiMedx Group, Inc. | 40.51 Million USD | 533.576% |
| MEI Pharma, Inc. | 26.38 Million USD | 765.929% |
| MacroGenics, Inc. | 2.01 Million USD | 8809.569% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 41045.462% |
| Mereo BioPharma Group plc | -26.05 Million USD | -574.209% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -1389.721% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | -39.981% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 124.659% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -709.868% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -1006.247% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -1552.14% |
| NextCure, Inc. | -59.03 Million USD | -197.552% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -242.982% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -1662.36% |
| Onconetix, Inc. | -36.7 Million USD | -378.583% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 7960.045% |
| Opthea Limited | -200.01 Million USD | 12.172% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -199.204% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -6284.405% |
| PDS Biotechnology Corporation | -40.08 Million USD | -338.249% |
| Precigen, Inc. | -89.22 Million USD | -96.884% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -671.778% |
| Prime Medicine, Inc. | -193.75 Million USD | 9.335% |
| PureTech Health plc | -11.62 Million USD | -1410.897% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 25.758% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 103.774% |
| Replimune Group, Inc. | -230.19 Million USD | 23.687% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -184413.906% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -934.521% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -877.397% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 59.201% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -628.57% |
| Sesen Bio, Inc. | -50.84 Million USD | -245.539% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -100.936% |
| Solid Biosciences Inc. | -93.43 Million USD | -88.017% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 23.602% |
| SciSparc Ltd. | -5.28 Million USD | -3225.861% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -158.665% |
| TG Therapeutics, Inc. | 26.1 Million USD | 773.073% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | -53.978% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -2351.807% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 46.154% |
| UroGen Pharma Ltd. | -63.83 Million USD | -175.214% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -182.444% |
| XOMA Corporation | -39.36 Million USD | -346.298% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 36.236% |
| AbCellera Biologics Inc. | -192.15 Million USD | 8.579% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -209.532% |
| Cassava Sciences, Inc. | -95.68 Million USD | -83.59% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -295.331% |
| Precision BioSciences, Inc. | -32.04 Million USD | -448.255% |
| Dyadic International, Inc. | -8.22 Million USD | -2034.6% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -1641.741% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -60268.385% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -500.424% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | -43.399% |
| IGM Biosciences, Inc. | -253.35 Million USD | 30.663% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | -64.022% |
| Acelyrin, Inc. | -381.52 Million USD | 53.955% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -247.37% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 272.69% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -782.224% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -626.939% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | -11.754% |
| Senti Biosciences, Inc. | -61.33 Million USD | -186.409% |
| Mesoblast Limited | -61.33 Million USD | -186.433% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | -22.675% |
| ChromaDex Corporation | -3.89 Million USD | -4411.351% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -3566.352% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -2457.833% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 71160.126% |
| Seer, Inc. | -97.88 Million USD | -79.468% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -640.139% |
| Novavax, Inc. | -487.39 Million USD | 63.957% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -7708.62% |
| Fate Therapeutics, Inc. | -172.22 Million USD | -1.999% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -236.872% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 22.01% |
| Celcuity Inc. | -58.3 Million USD | -201.273% |
| ContextLogic Inc. | -324 Million USD | 45.78% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | -10.451% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | -127.134% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 112.12% |
| Amarin Corporation plc | -50.9 Million USD | -245.121% |
| AnaptysBio, Inc. | -143.16 Million USD | -22.707% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -520.508% |
| Aptorum Group Limited | -9.59 Million USD | -1730.108% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 25.266% |
| Ardelyx, Inc. | -55.35 Million USD | -217.361% |
| Celularity Inc. | -183.94 Million USD | 4.498% |
| Omeros Corporation | -163.61 Million USD | -7.372% |
| Humacyte, Inc. | -96.45 Million USD | -82.123% |
| Immunocore Holdings plc | -59.64 Million USD | -194.51% |
| IO Biotech, Inc. | -91.22 Million USD | -92.564% |
| GT Biopharma, Inc. | 5.97 Million USD | 3038.15% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -139.878% |
| Summit Therapeutics Inc. | 1 Million USD | 17649.65% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -468.444% |
| Pulmatrix, Inc. | -12.64 Million USD | -1289.151% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 65.304% |
| Evogene Ltd. | -23.2 Million USD | -657.076% |
| CorMedix Inc. | -48.88 Million USD | -259.343% |
| BioLineRx Ltd. | -57.06 Million USD | -207.867% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -441.312% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -471.477% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 46.821% |
| scPharmaceuticals Inc. | -46.06 Million USD | -281.39% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | -61.922% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 262.173% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1389.294% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -628.57% |
| Akero Therapeutics, Inc. | -148.63 Million USD | -18.193% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -1186.692% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -588.397% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | -56.425% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | -113.627% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -206.177% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -886.385% |
| Daré Bioscience, Inc. | -30.7 Million USD | -472.193% |
| bluebird bio, Inc. | -167.16 Million USD | -5.091% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 156.617% |
| DBV Technologies S.A. | -85.98 Million USD | -104.313% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 24.765% |
| Galecto, Inc. | -37.51 Million USD | -368.221% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -426.185% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -270.882% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 15.008% |
| GlycoMimetics, Inc. | -39.12 Million USD | -349.036% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 22.759% |
| ADMA Biologics, Inc. | 5.12 Million USD | 3531.094% |
| Clene Inc. | -43.24 Million USD | -306.263% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 41.358% |
| Aptose Biosciences Inc. | -52.26 Million USD | -236.099% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | -63.047% |
| Soligenix, Inc. | -7.85 Million USD | -2137.048% |
| Century Therapeutics, Inc. | -121.2 Million USD | -44.934% |
| Kura Oncology, Inc. | -164.95 Million USD | -6.497% |
| Surrozen, Inc. | -41.13 Million USD | -327.104% |
| TScan Therapeutics, Inc. | -80.09 Million USD | -119.321% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -18242.367% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -3976.862% |
| Autolus Therapeutics plc | -156.77 Million USD | -12.057% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -107.51% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -781.268% |
| Caribou Biosciences, Inc. | -112.53 Million USD | -56.106% |
| GRI Bio, Inc. | -10.89 Million USD | -1511.965% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -3790.237% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -147.342% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -69.254% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -360.68% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -1045.868% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -2035.474% |
| Jaguar Health, Inc. | -33.13 Million USD | -430.235% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -1015.857% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -209.037% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -661.87% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 33.957% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 9.419% |
| Verastem, Inc. | -83.16 Million USD | -111.231% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | -11.025% |
| Histogen Inc. | -10.5 Million USD | -1572.589% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -1130.221% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -159.0% |
| Surrozen, Inc. | -41.13 Million USD | -327.104% |
| Organovo Holdings, Inc. | -14.8 Million USD | -1086.492% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 5477867.384% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -2006.883% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | -5.784% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -256.633% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -1066.865% |
| Kronos Bio, Inc. | -121.83 Million USD | -44.194% |
| Turnstone Biologics Corp. | -56.23 Million USD | -212.395% |
| Synaptogenix, Inc. | -8.3 Million USD | -2014.618% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -1045.264% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -54626.48% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -178.637% |
| Exelixis, Inc. | 196.6 Million USD | 189.354% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | -24.23% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 64.526% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -170.327% |
| ESSA Pharma Inc. | -26.45 Million USD | -564.033% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -4291.859% |
| Avid Bioservices, Inc. | -11.48 Million USD | -1430.111% |
| Insmed Incorporated | -654.73 Million USD | 73.169% |
| MediWound Ltd. | -4.89 Million USD | -3490.272% |
| OmniAb, Inc. | -49.73 Million USD | -253.244% |
| Alector, Inc. | -142.89 Million USD | -22.94% |
| Seres Therapeutics, Inc. | -85.43 Million USD | -105.623% |
| Zai Lab Limited | -366.57 Million USD | 52.077% |
| AlloVir, Inc. | -190.14 Million USD | 7.612% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 39.556% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | -60.069% |
| Aura Biosciences, Inc. | -83.69 Million USD | -109.893% |
| Immunic, Inc. | -99.11 Million USD | -77.246% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | -33.418% |
| Veracyte, Inc. | -49.4 Million USD | -255.547% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -2386.887% |
| FibroGen, Inc. | -261.4 Million USD | 32.797% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1476.806% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 302.359% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -2409.124% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -838.576% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -591.024% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 540.391% |
| Fortrea Holdings Inc. | 167.3 Million USD | 205.004% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | -30.825% |
| XBiotech Inc. | -35.76 Million USD | -391.17% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -170.327% |
| Keros Therapeutics, Inc. | -152.17 Million USD | -15.439% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 33308.318% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -169.229% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | -68.18% |
| Agenus Inc. | -145.92 Million USD | -20.386% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -584.294% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -329.863% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 65.985% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -213.582% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | -51.005% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -692.402% |
| C4 Therapeutics, Inc. | -122.1 Million USD | -43.872% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -3079.268% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -591.84% |
| Lantern Pharma Inc. | -15.78 Million USD | -1012.786% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| Ainos, Inc. | -8.77 Million USD | -1902.394% |
| Pluri Inc. | -20.22 Million USD | -768.588% |
| Prothena Corporation plc | -190.1 Million USD | 7.594% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | -37.032% |
| Rallybio Corporation | -72.37 Million USD | -142.731% |
| Kodiak Sciences Inc. | -259.02 Million USD | 32.179% |
| Cue Biopharma, Inc. | -46.05 Million USD | -281.464% |
| MeiraGTx Holdings plc | -57.05 Million USD | -207.916% |
| Annexon, Inc. | -141.57 Million USD | -24.084% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -173.649% |
| Moderna, Inc. | -3.28 Billion USD | 94.649% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -806.835% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -621.001% |
| Blueprint Medicines Corporation | -474.61 Million USD | 62.986% |
| Immix Biopharma, Inc. | -16.13 Million USD | -988.72% |
| CalciMedica, Inc. | -34.18 Million USD | -413.826% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | -28.144% |
| Scholar Rock Holding Corporation | -168.45 Million USD | -4.287% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -198.813% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 30.397% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -432.888% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | -73.563% |
| Nutriband Inc. | -5.12 Million USD | -3329.903% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -305.972% |
| Vor Biopharma Inc. | -114.37 Million USD | -53.598% |
| Roivant Sciences Ltd. | -996.51 Million USD | 82.371% |
| Alkermes plc | 495.04 Million USD | 135.486% |
| ProKidney Corp. | -147.66 Million USD | -18.963% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -172.212% |
| Arcellx, Inc. | -64.14 Million USD | -173.867% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 68.933% |
| Tango Therapeutics, Inc. | -111.75 Million USD | -57.19% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -86866.337% |
| Atai Life Sciences N.V. | -36.31 Million USD | -383.798% |
| Renovaro Biosciences Inc. | -79.51 Million USD | -120.924% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | -116.044% |
| MediciNova, Inc. | -9.87 Million USD | -1678.062% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | -39.488% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -11380.322% |
| GeoVax Labs, Inc. | -26.66 Million USD | -558.718% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 21.92% |
| Biomea Fusion, Inc. | -124.62 Million USD | -40.966% |
| RenovoRx, Inc. | -11.39 Million USD | -1442.335% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 7.706% |
| Geron Corporation | -174.78 Million USD | -0.509% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -485.086% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | -63.999% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 24.758% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -668.637% |
| Royalty Pharma plc | 1.88 Billion USD | 109.308% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 15.476% |
| Imunon, Inc. | -19.87 Million USD | -783.738% |
| BioAtla, Inc. | -122.24 Million USD | -43.71% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 41.5% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -323.847% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | -5.776% |
| Structure Therapeutics Inc. | -102.45 Million USD | -71.456% |
| 89bio, Inc. | -134.46 Million USD | -30.647% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | -76.992% |
| aTyr Pharma, Inc. | -52.17 Million USD | -236.678% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | -109.595% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 25.107% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -2084.35% |
| Akari Therapeutics, Plc | -16.8 Million USD | -945.542% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 93192.959% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 138.87% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | -7.468% |
| Liquidia Corporation | -70.05 Million USD | -150.777% |
| Entera Bio Ltd. | -8.8 Million USD | -1895.366% |
| GH Research PLC | -41.15 Million USD | -326.875% |
| Vericel Corporation | 2.86 Million USD | 6233.799% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -147.474% |
| Xencor, Inc. | -125.87 Million USD | -39.562% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -12214.508% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -1045.868% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -771.492% |
| Vaxcyte, Inc. | -464.88 Million USD | 62.212% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 16.551% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -1505.483% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -2649.762% |
| Portage Biotech Inc. | -18.19 Million USD | -865.284% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -11380.322% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | -67.972% |
| OncoCyte Corporation | -23.12 Million USD | -659.728% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1454.57% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1433.337% |
| Purple Biotech Ltd. | -22.22 Million USD | -690.425% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -510.481% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -506.539% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | -4.279% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -2640.593% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -495.418% |
| United Therapeutics Corporation | 1.38 Billion USD | 112.667% |
| HilleVax, Inc. | -132.46 Million USD | -32.617% |
| Silo Pharma, Inc. | -3.62 Million USD | -4744.502% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -2772.078% |
| Pharming Group N.V. | 9.87 Million USD | 1878.597% |
| Tharimmune, Inc. | -9.3 Million USD | -1788.421% |
| Genprex, Inc. | -31.06 Million USD | -465.579% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -109.171% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 6.321% |
| Pyxis Oncology, Inc. | -78.49 Million USD | -123.806% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -22893.717% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 116513.084% |
| OKYO Pharma Limited | -15.74 Thousand USD | -1115570.331% |
| Savara Inc. | -59.13 Million USD | -197.079% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -771.432% |
| Curis, Inc. | -45.13 Million USD | -289.18% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -1056.41% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -557.111% |
| BeiGene, Ltd. | -1.12 Billion USD | 84.379% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | -94.456% |
| Erasca, Inc. | -121.31 Million USD | -44.812% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -3804.902% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -3804.902% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -312.288% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -3010.34% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -193.511% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | -26.352% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 14.664% |
| Adicet Bio, Inc. | -136.53 Million USD | -28.664% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -90.784% |
| Aditxt, Inc. | -25.45 Million USD | -590.047% |
| Adagene Inc. | -14.95 Million USD | -1075.002% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2303.142% |
| Quantum-Si incorporated | -91.8 Million USD | -91.355% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 238.921% |
| Compugen Ltd. | -12.51 Million USD | -1303.579% |
| Generation Bio Co. | -133.3 Million USD | -31.787% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -111.577% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | -104.215% |
| Invivyd, Inc. | -196.61 Million USD | 10.652% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 53.048% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -1794.079% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 746.947% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -1608.041% |
| 2seventy bio, Inc. | -206.41 Million USD | 14.895% |
| Instil Bio, Inc. | -146.12 Million USD | -20.223% |
| Capricor Therapeutics, Inc. | -23 Million USD | -663.493% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -4013.768% |
| GeoVax Labs, Inc. | -26.66 Million USD | -558.718% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -378.288% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 3677.655% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | -10.901% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 74.328% |
| Evaxion Biotech A/S | -21.4 Million USD | -720.782% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -164.507% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 19.294% |
| Tyra Biosciences, Inc. | -79.59 Million USD | -120.716% |
| Cingulate Inc. | -22.95 Million USD | -665.388% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -2254.537% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -371.185% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -200.953% |
| Clearmind Medicine Inc. | -8.71 Million USD | -1916.747% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -136.302% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -7095.502% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -74.231% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 53.767% |
| ImmunityBio, Inc. | -436.18 Million USD | 59.725% |
| Korro Bio, Inc. | -80.9 Million USD | -117.136% |
| Kineta, Inc. | -15.71 Million USD | -1017.933% |
| BioVie Inc. | -31.95 Million USD | -449.831% |
| Codexis, Inc. | -49.28 Million USD | -256.456% |
| Celularity Inc. | -183.94 Million USD | 4.498% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -1025.165% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 20.693% |
| Virax Biolabs Group Limited | -6.6 Million USD | -2558.014% |
| Cibus, Inc. | -314.58 Million USD | 44.158% |
| IN8bio, Inc. | -28.5 Million USD | -516.306% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | -56.016% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -528.41% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 23.624% |
| Eyenovia, Inc. | -24.1 Million USD | -628.747% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 492.265% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -54119.753% |
| Elevation Oncology, Inc. | -41.46 Million USD | -323.643% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -138.025% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -290.261% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | -42.272% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -468.849% |
| Moolec Science SA | -52.07 Million USD | -237.341% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -240.41% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -334.649% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | -46.892% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -262.412% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1784.033% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -746.989% |
| Humacyte, Inc. | -96.45 Million USD | -82.123% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | -122.722% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 4435.439% |
| Genelux Corporation | -24.16 Million USD | -626.969% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -419.74% |
| Notable Labs, Ltd. | -14.4 Million USD | -1119.944% |
| Immunovant, Inc. | -269.97 Million USD | 34.931% |
| Quantum-Si incorporated | -91.8 Million USD | -91.355% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -809.84% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -72.207% |
| Acasti Pharma Inc. | -11.3 Million USD | -1454.482% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -689.422% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -374.405% |
| PepGen Inc. | -83.58 Million USD | -110.179% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -667.227% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -3581.511% |
| Immuneering Corporation | -58.06 Million USD | -202.566% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 5477867.384% |
| Belite Bio, Inc | -31.52 Million USD | -457.176% |
| XOMA Corporation | -39.36 Million USD | -346.298% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -160.459% |
| Bionomics Limited | -9.83 Million USD | -1685.83% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -407.635% |
| uniQure N.V. | -253.1 Million USD | 30.592% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -2303.142% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -35.65% |
| Forte Biosciences, Inc. | -32.47 Million USD | -440.912% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -2082.133% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -522.531% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -54119.753% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1476.806% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -1004.786% |
| Altimmune, Inc. | -87.93 Million USD | -99.775% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | -43.706% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -407.635% |
| Peak Bio, Inc. | -1356.23 USD | -12952865.205% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -261.48% |
| Benitec Biopharma Inc. | -22.49 Million USD | -681.112% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 27.499% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -515.464% |
| Zura Bio Limited | -60.56 Million USD | -190.065% |
| PolyPid Ltd. | -20.26 Million USD | -766.959% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -515.464% |
| argenx SE | -216.02 Million USD | 18.679% |
| Immunome, Inc. | -28.27 Million USD | -521.386% |
| Verona Pharma plc | -52.46 Million USD | -234.82% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | -85.363% |
| Shattuck Labs, Inc. | -87.61 Million USD | -100.504% |
| CervoMed Inc. | -2.17 Million USD | -7988.499% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -1284.007% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -264.661% |
| Moolec Science SA | -52.07 Million USD | -237.341% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -924.925% |
| Design Therapeutics, Inc. | -66.32 Million USD | -164.865% |
| Leap Therapeutics, Inc. | -80.98 Million USD | -116.914% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -365.356% |
| Achilles Therapeutics plc | -70.44 Million USD | -149.385% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -7095.502% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -216.914% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -247.521% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -169.118% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -224.658% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -287.147% |
| Beam Therapeutics Inc. | -156.47 Million USD | -12.27% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | -28.707% |
| AEON Biopharma, Inc. | -48.36 Million USD | -263.251% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -168.755% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | -114.412% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -1322.443% |
| NeurAxis, Inc. | -6.66 Million USD | -2535.939% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 58.901% |
| Lumos Pharma, Inc. | -36.57 Million USD | -380.372% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 3113.631% |
| Palisade Bio, Inc. | -12.28 Million USD | -1330.437% |
| Nutriband Inc. | -5.12 Million USD | -3329.903% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | -66.993% |
| Neurogene Inc. | -52.28 Million USD | -235.983% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -1992.33% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | -88.858% |
| Athira Pharma, Inc. | -116.7 Million USD | -50.529% |
| HCW Biologics Inc. | -23.57 Million USD | -645.129% |
| XOMA Corporation | -39.36 Million USD | -346.298% |
| Nektar Therapeutics | -243.1 Million USD | 27.739% |
| Arvinas, Inc. | -394.8 Million USD | 55.504% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 93192.959% |
| Merus N.V. | -149.2 Million USD | -17.737% |
| Omega Therapeutics, Inc. | -93.49 Million USD | -87.905% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -461.971% |
| Rezolute, Inc. | -68.42 Million USD | -156.744% |
| Clene Inc. | -43.24 Million USD | -306.263% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -1039.086% |
| BeyondSpring Inc. | -21.54 Million USD | -715.562% |
| Synlogic, Inc. | -55.16 Million USD | -218.471% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -1353.877% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -1550.742% |
| Peak Bio, Inc. | -1356.23 USD | -12952865.205% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -441.112% |
| Krystal Biotech, Inc. | 17.9 Million USD | 1081.189% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | -48.343% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 48.536% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -3713.624% |
| MannKind Corporation | 15.12 Million USD | 1261.161% |
| Ikena Oncology, Inc. | -74.39 Million USD | -136.128% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -1294.997% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 964.23% |
| Gossamer Bio, Inc. | -172.15 Million USD | -2.045% |
| CohBar, Inc. | -12.06 Million USD | -1355.955% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -588.667% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -485.086% |
| Legend Biotech Corporation | -477.87 Million USD | 63.239% |
| Mural Oncology plc | -192.72 Million USD | 8.846% |
| Disc Medicine, Inc. | -91.02 Million USD | -92.993% |
| Champions Oncology, Inc. | -5.05 Million USD | -3375.9% |
| REGENXBIO Inc. | -239.46 Million USD | 26.639% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -1539.009% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -215.073% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -353.133% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | -55.729% |
| Vaxart, Inc. | -74.72 Million USD | -135.098% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -398.951% |
| Cellectis S.A. | -98.09 Million USD | -79.084% |
| Longeveron Inc. | -20.06 Million USD | -775.733% |
| Repare Therapeutics Inc. | -114.27 Million USD | -53.73% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 60.001% |
| Inozyme Pharma, Inc. | -74.81 Million USD | -134.818% |
| Revolution Medicines, Inc. | -430.58 Million USD | 59.201% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -2693.322% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -470.567% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -135.517% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 3682.949% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -1502.116% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.815% |
| Denali Therapeutics Inc. | -179.97 Million USD | 2.39% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -184413.906% |
| Veru Inc. | -89.97 Million USD | -95.244% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -553.59% |
| Cingulate Inc. | -22.95 Million USD | -665.388% |
| Passage Bio, Inc. | -98.34 Million USD | -78.636% |
| Context Therapeutics Inc. | -25.06 Million USD | -600.99% |
| Exicure, Inc. | -15.53 Million USD | -1030.523% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 14.749% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -375.097% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -2846.233% |
| Nuvalent, Inc. | -149.49 Million USD | -17.513% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -2060.146% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | -104.522% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -482.119% |
| OmniAb, Inc. | -49.73 Million USD | -253.244% |
| Anew Medical, Inc. | -1.3 Million USD | -13404.505% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -1320.835% |
| Lipocine Inc. | -16.32 Million USD | -976.246% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -163.495% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -136.427% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -360.68% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -350.279% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -691.922% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 67.771% |
| Ocugen, Inc. | -64.82 Million USD | -170.986% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | -89.772% |
| Q32 Bio Inc. | -86.5 Million USD | -103.084% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -937.821% |
| Alumis Inc. Common Stock | -156.89 Million USD | -11.971% |
| Equillium, Inc. | -12.13 Million USD | -1347.29% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -200.438% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -2122.754% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -831.405% |
| Dominari Holdings Inc. | -22.44 Million USD | -682.852% |
| Edesa Biotech, Inc. | -8.19 Million USD | -2044.92% |
| vTv Therapeutics Inc. | -25.41 Million USD | -591.295% |
| Bio-Techne Corporation | 326.66 Million USD | 153.778% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 54.355% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 181.183% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | -33.99% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -369.322% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | -16.261% |
| Nkarta, Inc. | -120.48 Million USD | -45.809% |
| BioCardia, Inc. | -11.56 Million USD | -1419.654% |
| Iterum Therapeutics plc | -34.58 Million USD | -408.016% |